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Abstract
Background: Anti-Wolbachia treatment with doxycycline is effective in sterilising and killing adult Onchocerca
volvulus nematodes, proving superior to ivermectin and of great potential as an alternative approach for the
treatment and control of onchocerciasis, particularly in areas of Loa loa co-endemicity. Nevertheless, the length of
the required treatment poses potential logistical problems and risk of poor compliance, raising a barrier to the use
of doxycycline in Mass Drug Administration (MDA) strategies. In 2007 and 2008 a feasibility trial of community-
directed treatment with doxycycline was carried out in two health districts in Cameroon, co-endemic for O.
volvulus and L. loa. With 17,519 eligible subjects, the therapeutic coverage was 73.8% with 97.5% compliance,
encouraging the feasibility of using doxycycline community-directed delivery in restricted populations of this size.
The current study evaluated the effectiveness of this community-directed delivery of doxycycline four years after
delivery.
Findings: Infection with O. volvulus was evaluated by skin biopsy and nodule palpation. Of the 507 subjects
recruited, 375 had completed the treatment with doxycycline followed by one or two rounds of annual ivermectin
MDA and 132 received one or two rounds of annual ivermectin MDA alone. Statistically significant lower
microfilarial prevalence (17.0% [doxycycline plus ivermectin group], 27.0% [ivermectin only group], p = 0.014) and
load (p = 0.012) were found in people that had received doxycycline followed by ivermectin compared to those
who received ivermectin only.
Conclusions: This study demonstrates the long-term effectiveness of doxycycline treatment delivered with a
community-directed strategy even when evaluated four years after delivery in an area of ongoing transmission.
This finding shows that a multi-week course of treatment is not a barrier to community-delivery of MDA in
restricted populations of this size and supports its implementation to compliment existing control strategies for
onchocerciasis, where needed.
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Background
Onchocerciasis or ‘river blindness’ is a debilitating disease
affecting an estimated 37 million people in Sub Saharan
Africa and Latin America, with at least 500,000 people
visually impaired and 270,000 blinded by the disease [1].
Annual or biannual Mass Drug Administration (MDA) of
ivermectin is the current strategy implemented by the
African Programme for Onchocerciasis Control [2]. At the
standard dose of 150 μg/kg, it is highly effective at redu-
cing dermal microfilarial loads, but is only marginally
active against adult worms [3,4], requiring sustained deliv-
ery for at least 15-17 years in order to interrupt transmis-
sion in areas of moderate transmission [5]. Moreover, the
severe and occasionally fatal adverse reactions following
ivermectin intake in people with high loads of Loa loa
microfilariae (mf) are an obstacle to the implementation of
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city [6,7].
Four to six week courses of doxycycline have been pro-
ven in clinical trials to be highly effective at blocking
embryogenesis of adult worms, and leading to a macrofi-
laricidal rate of 60-70% [8-10]. This demonstrates super-
ior efficacy of doxycycline compared to ivermectin, and
provides an important alternative treatment for oncho-
cerciasis in areas of L. loa co-endemicity, in areas where
evidence of sub-optimal efficacy of ivermectin occurs
[11-13], and in programme endgame situations [14] to
achieve elimination of the infection. Doxycycline targets
the bacterial endosymbiont Wolbachia, and so can be
used safely in areas where the Wolbachia-free L. loa is
co-endemic, as it has no microfilaricidal activity against
L. loa [10].
By virtue of its pronounced macrofilaricidal and
embryostatic effects, it is expected that community-wide
distribution of doxycycline will lead to long-term reduc-
tions in microfilaridermia. Nevertheless, one barrier to
the widespread use of doxycycline is the perceived risk of
poor compliance due to the length of treatment regimes
[15]. In a phase III trial, Wanji and colleagues countered
this perception by demonstrating the feasibility and safety
of large-scale delivery of doxycycline using a community-
directed strategy in areas of L. loa co-endemicity in
Cameroon, naive to onchocerciasis control programmes
[16]. Of 17,519 eligible subjects, 12,936 were treated with
doxycycline in 2007 or 2008, giving a therapeutic cover-
age of 73.83% for the eligible population. Moreover, the
6 week course of treatment was completed by 97.5% of
individuals who started it, as assessed by directly
observed drug intake. Following community-directed
delivery of doxycycline, communities received two
rounds of annual ivermectin MDA, which was distributed
as part of the national control programme that was
extended to these areas. In addition to showing a high
level of coverage and compliance to a 6 week course of
doxycycline, the feasibility study highlighted the safety of
this regime, in which there were no Severe Adverse
Events (SAEs) in any of the 17,519 people during treat-
ment with doxycycline, yet when treated with ivermectin
two SAEs were reported, as observed in other L. loa
co-endemic areas [6,7]. The current single-blind evalua-
tion trial was carried out to assess the long-term effec-
tiveness of this community-directed treatment with
doxycycline in reducing skin microfilarial prevalence and
load four years after implementation in an area of
ongoing infection transmission.
Methods
The study was approved by the Research Ethics Commit-
tee of the Liverpool School of Tropical Medicine (UK)
and the Institutional Review Board of the Medical
Research Station of Kumba (Cameroon), and registered
in the ISRCTN register (ISRCTN95189962). The study
was carried out in three health areas of Mbanga health
district in the littoral region of Cameroon. Community-
directed delivery of doxycycline was implemented in
2007 and 2008 [16], followed by two rounds of ivermec-
tin MDA, as part of the national control programme.
Participants of both sexes, aged 19 or above, were
recruited from those who completed the 6 week course
of doxycycline MDA in 2007 or 2008, plus one or two
annual treatments of ivermectin MDA, and those who
received ivermectin MDA alone. End-points were micro-
filarial prevalence (primary outcome) and load in the two
treatment groups. Presence and number of palpable
nodules was also assessed.
For the sample size calculation, the expected reduction
in microfilaridermia prevalence in the two groups was
estimated using the Rapid Evidence Assessment of
O. volvulus prevalence in the investigated areas [16,17]
and its expected change after the implemented treat-
ments [10,12]. A sample size of 500 subjects had a 90%
power to detect a difference in prevalence of microfilari-
dermia of 16.0% (expected prevalence in the doxycycline
plus ivermectin group) versus 26.8%. This was consid-
ered the smallest difference between groups relevant for
effectiveness assessment. Moreover, this sample size was
considered adequate to obtain an accurate estimate of
differences between groups and also in the light of the
expected microfilaridermia prevalence after two rounds
of ivermectin MDA (58.6%).
Villages in each health area were randomly selected
and inhabitants were invited to participate in the study.
After a thorough explanation of the study’sa i ma n d
execution in the local language, all participants gave
informed consent prior to examination. For the assess-
ment of microfilarial prevalence and load, two skin
biopsies (skin snips) from the iliac crests were taken
using a sterile corneoscleral punch and incubated in
saline solution in microtitre plates overnight (10-18 h).
The number of mf was counted and the skin biopsies
weighed to calculate the number of mf per mg of skin
(mf/mg). Body palpation was carried out to assess the
presence and number of palpable onchocercal nodules.
Both mf counting and body palpation were carried out
in a blinded manner with regard to the treatment
group.
Statistical analysis
Differences in microfilarial and nodule prevalence
between groups were assessed by Fisher’sE x a c tt e s t .
Differences in microfilarial and nodule burden between
groups were assessed by Mann-Whitney U test. A
p-value ≤ 0.05 was considered significant. All analysis
was carried out using SPSS Statistics 17.0 (IBM).
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Five-hundred and seven people, 260 males and 247
females, were recruited from 17 villages of the three health
areas investigated. Of those, 375 had completed the treat-
ment with doxycycline followed by one or two annual
rounds of ivermectin MDA and 132 received one or two
annual rounds of ivermectin MDA alone (Table 1). There
was no difference in the proportion of people who had
received one versus two rounds of ivermectin between the
groups (53.1% [one round of ivermectin in doxycycline
plus ivermectin group], 59.8% [one round of ivermectin in
ivermectin only group], p = 0.858).
Microfilaridermia prevalence was significantly lower in
people who received doxycycline followed by one or two
annual rounds of ivermectin MDA compared to those
who received ivermectin MDA alone (p = 0.014, Figure 1A
and Table 2). The percentage of amicrofilaridermic people
was 83.2% in the group that had received doxycycline fol-
lowed by ivermectin MDA compared to 73.2% in the
group that had received only ivermectin MDA. A signifi-
cant difference was also found in microfilarial burden (p =
0.012, Figure 1B and Table 2), with people that had
received doxycycline harbouring significantly lower
microfilarial loads. When evaluating those with palpable
nodules, we found that microfilarial loads were signifi-
cantly lower in those who received doxycycline (p =0 . 0 3 2 ,
Figure 1C and Table 2). In this subset of people, microfi-
laridermia prevalence was also lower in the group that had
received doxycycline, even though it did not reach statisti-
cal significance (p = 0.091, Table 2). No differences were
detected in palpable nodule prevalence and burden
between the groups.
Discussion
Our findings show that delivery of doxycycline with a
community-directed approach is not only feasible, but
also effective in reducing microfilaridermia prevalence
and loads. Importantly, these results were obtained four
years after implementation in an area of ongoing trans-
mission and naive to previous control measures, and so
demonstrate the long-term efficacy of community-wide
doxycycline treatment.
Although this study demonstrates the feasibility and
effectiveness of doxycycline treatment, the contraindica-
tions of this drug in children < 9 years old and in preg-
nancy and the desirability for shorter treatment regimes
Table 1 Characteristics of the investigated population
Treatment group Health district Males (%) Females (%) Total Mean age years (range)
Doxycycline + ivermectin All 210 (56%) 165 (44%) 375 43.16 (19-81)
Matouke 104 (57.14%) 78 (42.86%) 182 43.66 (19-74)
Mombo 68 (54.84%) 56 (45.16%) 124 42.39 (19-81)
Kotto 38 (55.07%) 31 (44.93%) 69 43.23 (23-78)
Ivermectin only All 50 (37.88%) 82 (62.12%) 132 36.86 (19-71)
Matouke 17 (26.56%) 47 (73.44%) 64 34.78 (19-62)
Mombo 14 (53.85%) 12 (46.15%) 26 40.54 (20-69)
Kotto 19 (45.24%) 23 (54.76%) 42 38.00 (20-71)
Figure 1 Differences in microfilarial prevalence and load between groups. Investigated groups are people who received community-
directed doxycycline followed by one or two rounds of annual ivermectin MDA (DOXY + IVM, N = 375) and those who received one or two
rounds of annual ivermectin MDA only (IVM, N = 132). A) Difference in microfilaridermia prevalence between groups; the graph shows mean
and 95% CI. Fisher’s Exact test. B) Difference in microfilarial loads between groups; the graph shows median and 5-95 percentiles of mf/mg of
skin in Mf
+ subjects. Mann-Whitney U test. C) Difference in microfilarial loads in people with palpable nodules (DOXY+IVM, N = 70; IVM, N = 26);
the graph shows median and 5-95 percentiles of mf/mg of skin. Mann-Whitney U test.
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which aims to discover and develop alternative anti-wol-
bachial drugs and regimes that overcome exclusion of
these patient groups and reduce treatment timeframes
[18].
The lack of difference in nodule prevalence and burden
between groups most likely reflects the ongoing transmis-
sion of the infection in the area, where new incoming
parasites may colonise already existing nodules [19]. Also,
although doxycycline has been demonstrated in phase II
trials to show a high rate of macrofilaricidal activity (60-
70%) [8,10,19], the rate of nodule re-absorption is not
known. All these factors, therefore, make the use of palp-
able nodule prevalence and burden less suitable to assess
the effectiveness of doxycycline in an area of ongoing
transmission and within the investigated timeframe from
distribution.
Our results should encourage the introduction of com-
munity-directed distribution of doxycycline and other
anti-wolbachial drugs and regimes in onchocerciasis con-
trol programmes, such as in restricted populations with
high risk of SAEs to ivermectin in L. loa co-endemic areas,
in populations with evidence of sub-optimal responsive-
ness to ivermectin and as an endgame tool to meet the
goal of elimination (as planned for the North-East focus of
onchocerciasis in Venezuela as part of the Onchocerciasis
Elimination Programme for the Americas [OEPA]). More-
over, as doxycycline is the first macrofilaricidal drug avail-
able for onchocerciasis, knowledge of its long-term impact
is of particular importance to address the practical aspects
of implementation of macrofilaricides within existing con-
trol programmes for onchocerciasis.
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